Albireo to Present at the William Blair Biotech Focus Conference 2021
08 Juli 2021 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced
that Ron Cooper, President and Chief Executive Officer, will
present at the William Blair Biotech Focus Conference on Thursday,
July 15, at 11:00 a.m. EDT.
The live webcast of the presentation will be accessible from the
Media & Investors page of Albireo’s website,
ir.albireopharma.com. To ensure a timely connection to the webcast,
it is recommended that users register at least 15 minutes prior to
the scheduled start time. An archived version of the webcasts will
be available for replay in the Events & Presentations section
of the Media & Investors page of Albireo’s website for 30 days
following the event.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, Bylvay, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3 trials
in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA
recently granted Priority Review and set a PDUFA goal date of July
20, 2021. In Europe, the EMA’s CHMP recently issued a positive
opinion and Bylvay is the only IBATi granted accelerated assessment
by the EMA. Bylvay has been provisionally accepted by both the FDA
and EMA as the brand name for odevixibat. The Company has also
initiated a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
moving ahead with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. The Boston Business Journal named Albireo one
of the 2020 Best Places to Work in Massachusetts for the second
consecutive year. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024